Status:
COMPLETED
Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication
Lead Sponsor:
Abbott Medical Devices
Conditions:
Shock
Eligibility:
All Genders
18+ years
Brief Summary
Although shock therapy is effective in terminating ventricular tachycardia (VT), it can be painful to the patient and repetitive shocks can decrease a patient's quality of life. Previous studies have ...
Eligibility Criteria
Inclusion
- Primary Prevention indication for ICD/ CRT-D
Exclusion
- No prior documented history of spontaneous VT/VF
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
1670 Patients enrolled
Trial Details
Trial ID
NCT00743522
Start Date
September 1 2008
End Date
December 1 2011
Last Update
February 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hall-Garcia Cardiology Associates
Houston, Texas, United States, 77598